CQP(SZ:000950)2022-05-04 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥15,878,655,477.15, representing a 9.80% increase compared to ¥14,461,217,356.50 in the same period last year[4] - Net profit attributable to shareholders was ¥111,888,762.43, a 40.70% increase from ¥79,524,791.42 year-on-year[4] - Total operating revenue for the current period reached ¥15,878,655,477.15, an increase of 9.8% compared to ¥14,461,217,356.50 in the previous period[26] - Net profit for the current period was ¥144,327,904.72, compared to ¥133,286,652.92 in the previous period, representing an increase of 8.0%[29] - The net profit attributable to the parent company was ¥111,888,762.43, up from ¥79,524,791.42, indicating a significant growth of 40.6%[30] - The total comprehensive income for the current period was ¥144,327,904.72, compared to ¥133,286,652.92 in the previous period, showing an increase of 8.0%[30] Cash Flow - The net cash flow from operating activities was -¥3,159,107,305.23, reflecting a 24.01% increase in outflow compared to -¥2,547,529,457.48 in the previous year[11] - Operating cash flow net amount was -3,159,107,305.23, compared to -2,547,529,457.48 in the previous period, indicating a decline in cash flow from operations[33] - Cash inflow from operating activities totaled 15,384,982,283.54, an increase from 13,271,781,013.99[33] - Cash outflow from operating activities was 18,544,089,588.77, compared to 15,819,310,471.47 in the previous period[33] - Investment activities generated a net cash flow of 74,238,524.35, a significant improvement from -370,370,973.25 in the prior period[36] - Cash inflow from investment activities was 190,848,493.61, significantly higher than 43,858,621.55 in the prior period[36] - Cash outflow from investment activities totaled 116,609,969.26, down from 414,229,594.80 year-over-year[36] - Financing activities produced a net cash flow of 2,583,847,229.80, up from 2,086,407,203.98 year-over-year[36] - Cash inflow from financing activities was 7,179,947,756.00, slightly lower than 7,352,747,582.06 in the previous period[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥52,383,341,339.08, up 5.40% from ¥49,700,081,320.97 at the end of the previous year[4] - The company's total current assets increased to approximately 43.97 billion RMB from 41.34 billion RMB at the beginning of the year, reflecting a growth of about 6.36%[18] - The total assets of the company reached approximately 52.38 billion RMB, up from 49.70 billion RMB, indicating an increase of about 5.36%[21] - The total liabilities of the company increased to approximately 33.67 billion RMB from 31.72 billion RMB, indicating a growth of about 6.14%[21] - Total liabilities increased to ¥40,472,842,190.39 from ¥37,933,537,693.05, marking a rise of 6.4%[26] - The company's total liabilities increased, with short-term borrowings rising by 2.07% to ¥12,219,952,344.04, while long-term borrowings decreased by 2.04% to ¥4,513,864,679.26[7] - The company’s total non-current liabilities increased to ¥6,806,996,055.93 from ¥6,209,456,696.33, reflecting a growth of 9.6%[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 65,555[12] - The largest shareholder, Chongqing Pharmaceutical Health Industry Co., Ltd., holds 38.14% of shares, totaling 664,900,806 shares[12] - The company reported a significant pledge of shares by major shareholders, with Chongqing Pharmaceutical Health Industry Co., Ltd. pledging 109,867,400 shares[12] Earnings and Expenses - The basic earnings per share rose by 20.00% to ¥0.06 from ¥0.05 in the same period last year[4] - Research and development expenses were recorded at ¥76,038.11, a decrease from ¥3,265,576.96 in the previous period[27] - Total operating costs amounted to ¥15,646,178,783.59, up from ¥14,590,776,932.08, reflecting a year-over-year increase of 7.2%[27]